Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: Bio-Rad is a multinational manufacturer and distributor of Life Science research and Clinical Diagnostics products. The company operates two primary segments: Life Science and Clinical Diagnostics. Approximately 65% of sales are international, creating exposure to foreign currency fluctuations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2006 |
Three Months Ended June 30, 2005 |
Six Months Ended June 30, 2006 |
Six Months Ended June 30, 2005 |
|---|---|---|---|---|
| Net Sales | $317,747 | $291,302 | $626,085 | $590,473 |
| Gross Profit | $184,662 | $160,643 | $360,190 | $327,049 |
| Gross Margin % | 58.1% | 55.1% | 57.5% | 55.4% |
| Net Income | $32,266 | $18,388 | $63,464 | $51,882 |
| Diluted EPS | $1.20 | $0.69 | $2.36 | $1.95 |
| Operating Cash Flow (6mo) | $11,492 (2006) vs $27,818 (2005) | |||
| Cash & Equivalents | $245,646 (as of June 30, 2006) | |||
| Total Debt (Long-term + Current) | $430,351 (as of June 30, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9.1% in Q2 2006 and 6.0% for the six-month period compared to 2005. On a currency-neutral basis, growth was 9.7% for Q2 and 9.0% for the six months, as a strengthening U.S. dollar negatively impacted reported sales by $1.9 million (Q2) and $17.5 million (6 months).
- Profitability: Net income surged 75% in Q2 2006 and 22% for the six-month period. Gross margins expanded to 58.1% in Q2 from 55.1% in the prior year, driven by the Clinical Diagnostics segment.
- One-Time Items:
- bioMérieux Settlement: The company recorded $11.7 million in revenue from a settlement of licensing disputes with bioMérieux, significantly boosting Clinical Diagnostics sales and margins.
- Legal Settlement: Operating cash flow decreased significantly due to a $45.0 million payment related to the settlement of the ABI lawsuit (MJ Research acquisition liability).
- Discontinued Operations: No discontinued operations activity in 2006; 2005 included a $4.0 million gain on the divestiture of the confocal microscopy product line.
- Accounting Change: The company adopted SFAS 123(R) effective January 1, 2006, recognizing share-based compensation expense. This reduced net income by $0.09 per share for the six months ended June 30, 2006.
Guidance, Outlook, and Risks
- Market Outlook: Management notes the diagnostic market is growing around 4% (currency neutral), while the life science market averages 5% growth. However, government-sponsored research spending has slowed in the U.S. and Japan, and BSE testing markets face pricing pressures.
- Liquidity: As of June 30, 2006, the company held $245.6 million in cash and cash equivalents, $188.3 million in short-term investments, and $145.6 million available under its revolving credit facility. Management believes this is adequate for operations and potential acquisitions.
- Risks and Contingencies:
- Legal Proceedings: An ongoing patent dispute with Applera Corporation regarding real-time PCR technology in Germany. While a patent was reinstated in July 2006, it remains subject to review. Management does not believe current lawsuits will have a material adverse effect.
- Currency: Approximately 65% of sales are international. A strengthening U.S. dollar continues to negatively impact reported sales.
- Regulatory: Pricing for routine diagnostic tests is impacted by declining government reimbursement schedules in the U.S., Japan, and Germany.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the $11.7 million bioMérieux settlement revenue, as it is a non-recurring item significantly impacting Q2 margins.
- Cash Flow Impact: Confirm the impact of the $45.0 million litigation settlement payment on future liquidity and working capital requirements.
- Legal Exposure: Monitor the status of the Applera patent dispute in Germany and potential injunctions or damages.
- Currency Hedging: Assess the company's strategy regarding the unhedged Brazilian Real exposure, which contributed to foreign exchange losses in the current period.
- Share-Based Compensation: Review the ongoing impact of SFAS 123(R) adoption on future earnings per share, with approximately $12 million of unrecognized compensation cost remaining.